BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tirzepatide (Mounjaro) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tirzepatide (Mounjaro)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07128082-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tirzepatide (Mounjaro): Phase 2 readout est. (NCT07128082)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2.\nStudy: The Long COVID Treatm
 ent Trial\nEstimated primary completion: December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07128082
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06727331-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Tirzepatide (Mounjaro): Phase 2 readout est. (NCT06727331)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2.\nStudy: Study of Tirzepatide 
 for Recovery and Alcohol Use Management\nEstimated primary completion: 1 M
 arch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatid
 e-mounjaro#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06727331
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06774079-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270305
DTEND;VALUE=DATE:20270306
SUMMARY:Tirzepatide (Mounjaro): Phase 4 readout est. (NCT06774079)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 4.\nStudy: Glucagon-like Peptide
 -1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD
 ) Patients\nEstimated primary completion: 5 March 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06774079
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07095517-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tirzepatide (Mounjaro): Phase 1 readout est. (NCT07095517)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 1.\nStudy: Pathways\, Risk Facto
 rs\, and mOleculeS to Prevent Early-onset Colorectal Tumors\nEstimated pri
 mary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tirzepatide-mounjaro#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07095517
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483801-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Tirzepatide (Mounjaro): Phase 4 readout est. (NCT07483801)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 4.\nStudy: DECODE - Haemodynamic
  Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies\nEstim
 ated primary completion: April 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/tirzepatide-mounjaro#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07483801
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07046819-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Tirzepatide (Mounjaro): Phase 2 readout est. (NCT07046819)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2.\nStudy: Tirzepatide in MetALD
 \nEstimated primary completion: 30 July 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07046819
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07191873-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Tirzepatide (Mounjaro): Phase 4 readout est. (NCT07191873)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 4.\nStudy: Tirzepatide in Idiopa
 thic Intracranial Hypertension Trial\nEstimated primary completion: August
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-mo
 unjaro#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07191873
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07756359-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Tirzepatide (Mounjaro): Phase 4 readout est. (NCT07756359)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 4.\nStudy: Tirzepatide for Ileal
  Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X0
 08)\nEstimated primary completion: September 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07756359
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06651177-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Tirzepatide (Mounjaro): Phase 2 readout est. (NCT06651177)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2.\nStudy: Evaluation of Tirzepa
 tide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disord
 er\nEstimated primary completion: 30 September 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06651177
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220473-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Tirzepatide (Mounjaro): Phase 2 readout est. (NCT07220473)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2.\nStudy: Tirzepatide to Slow B
 iological Aging\nEstimated primary completion: November 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07220473
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06657209-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Tirzepatide (Mounjaro): Phase 4 readout est. (NCT06657209)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 4\, Type 2 Diabetes.\nStudy: Nor
 mal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirze
 patide\nEstimated primary completion: 15 December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06657209
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06820281-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tirzepatide (Mounjaro): Phase 2 readout est. (NCT06820281)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2.\nStudy: Acute Metabolic Effec
 ts of Tirzepatide in Type 1 Diabetes\nEstimated primary completion: 31 Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepati
 de-mounjaro#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06820281
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07605247-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tirzepatide (Mounjaro): Phase 2 readout est. (NCT07605247)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2.\nStudy: Tirzepatide in the Tr
 eatment of Endometrial Cancer\nEstimated primary completion: January 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-mounjaro
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076
 05247
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284511-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tirzepatide (Mounjaro): Phase 2/3 readout est. (NCT07284511)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2/3.\nStudy: A Clinical Trial Us
 ing Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control 
 Their Blood Sugar\nEstimated primary completion: January 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07284511
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07602699-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Tirzepatide (Mounjaro): Phase 2 readout est. (NCT07602699)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2.\nStudy: Multi-Site Trial of T
 irzepatide for Smoking Cessation\nEstimated primary completion: March 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-mounjar
 o#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 602699
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07676331-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Tirzepatide (Mounjaro): Phase 2 readout est. (NCT07676331)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2.\nStudy: Clinical Study of Loc
 al and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patient
 s With Breast Cancer: The CLARA Trial\nEstimated primary completion: 1 Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-
 mounjaro#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07676331
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07468552-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:Tirzepatide (Mounjaro): Phase 2 readout est. (NCT07468552)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2.\nStudy: Trial of Tirzepatide 
 for the Treatment of Cannabis Use Disorder\nEstimated primary completion: 
 15 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tirzep
 atide-mounjaro#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07468552
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07906041-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Tirzepatide (Mounjaro): Phase 2 readout est. (NCT07906041)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2.\nStudy: Tirzepatide and Organ
 -specific Biological Aging\nEstimated primary completion: April 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-mounjaro#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07906041
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07202247-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280409
DTEND;VALUE=DATE:20280410
SUMMARY:Tirzepatide (Mounjaro): Phase 2 readout est. (NCT07202247)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2.\nStudy: Metabolic Interventio
 ns (Time-Restricted Eating\, GLP1 Receptor Agonist\, and Heart Healthy Die
 t) to Improve Cardiometabolic Health in Prostate Cancer Patients During An
 drogen Deprivation Therapy\, IMPACT-ADT Trial\nEstimated primary completio
 n: 9 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tirz
 epatide-mounjaro#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07202247
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976853-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Tirzepatide (Mounjaro): Phase 2 readout est. (NCT06976853)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2.\nStudy: Moving Beyond Inflamm
 ation as a Therapeutic Target for Crohn's Disease\nEstimated primary compl
 etion: May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tirz
 epatide-mounjaro#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06976853
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07812636-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Tirzepatide (Mounjaro): Phase 1 readout est. (NCT07812636)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 1.\nStudy: Tirzepatide and Levon
 orgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer\nEstimate
 d primary completion: 1 May 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/tirzepatide-mounjaro#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07812636
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07734870-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280525
DTEND;VALUE=DATE:20280526
SUMMARY:Tirzepatide (Mounjaro): Phase 2 readout est. (NCT07734870)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2.\nStudy: Tirzepatide for Treat
 ment of CCCA\nEstimated primary completion: 25 May 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07734870
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07734792-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Tirzepatide (Mounjaro): Phase 2/3 readout est. (NCT07734792)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2/3.\nStudy: Tirzepatide in Thro
 mbectomy-Treated Acute Ischemic Stroke: A Randomized Trial\nEstimated prim
 ary completion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/tirzepatide-mounjaro#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07734792
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07265752-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Tirzepatide (Mounjaro): Phase 2 readout est. (NCT07265752)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2.\nStudy: Tirzepatide for the T
 reatment of Cannabis Use Disorder\nEstimated primary completion: 30 June 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-moun
 jaro#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07265752
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07706088-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Tirzepatide (Mounjaro): Phase 4 readout est. (NCT07706088)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 4.\nStudy: Effect of Tirzepatide
  on Diabetic Peripheral Sensorimotor Neuropathy\nEstimated primary complet
 ion: 1 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tir
 zepatide-mounjaro#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07706088
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07573163-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Tirzepatide (Mounjaro): Phase 2 readout est. (NCT07573163)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2.\nStudy: Tirzepatide Following
  Adrenalectomy in Mild Autonomous Cortisol Secretion\nEstimated primary co
 mpletion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/tirzepatide-mounjaro#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07573163
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671248-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Tirzepatide (Mounjaro): Phase 3 readout est. (NCT07671248)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 3.\nStudy: Tirzepatide in the Tr
 eatment of Cannabis Use Disorder\nEstimated primary completion: 31 July 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-mounj
 aro#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07671248
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06939088-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Tirzepatide (Mounjaro): Phase 2 readout est. (NCT06939088)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2.\nStudy: Effects of Tirzepatid
 e on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol U
 se Disorder\nEstimated primary completion: 1 August 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06939088
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06246799-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Tirzepatide (Mounjaro): Phase 3 readout est. (NCT06246799)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 3\, Type 2 Diabetes.\nStudy: Com
 parative Effectiveness of Two Initial Combination Therapies in Patients Wi
 th Recent Onset Diabetes\nEstimated primary completion: 30 April 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-mounjaro#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0624679
 9
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07091734-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Tirzepatide (Mounjaro): Phase 2 readout est. (NCT07091734)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2.\nStudy: Tirzepatide for Parti
 al Lipodystrophy Treatment: A New Horizon in 2024\nEstimated primary compl
 etion: September 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tirzepatide-mounjaro#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07091734
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527910-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20300315
DTEND;VALUE=DATE:20300316
SUMMARY:Tirzepatide (Mounjaro): Phase 2 readout est. (NCT07527910)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2.\nStudy: A Phase 2a Study of A
 LN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous 
 PNPLA3-Related MASLD\nEstimated primary completion: 15 March 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-mounjaro#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07527910
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07946315-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20300501
DTEND;VALUE=DATE:20300502
SUMMARY:Tirzepatide (Mounjaro): Phase 2 readout est. (NCT07946315)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2.\nStudy: Tirzepatide for the R
 Eduction of AceTazolamide in Idiopathic Intracranial Hypertension\nEstimat
 ed primary completion: 1 May 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tirzepatide-mounjaro#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07946315
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07782359-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Tirzepatide (Mounjaro): Phase 1 readout est. (NCT07782359)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 1.\nStudy: Impact of Using a GLP
 1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorl
 atinib\nEstimated primary completion: June 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07782359
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07165028-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Tirzepatide (Mounjaro): Phase 3 readout est. (NCT07165028)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 3.\nStudy: A Master Protocol of 
 Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic 
 Liver Disease (SYNERGY-Outcomes)\nEstimated primary completion: August 203
 0. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-mounja
 ro#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7165028
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07825857-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20310701
DTEND;VALUE=DATE:20310702
SUMMARY:Tirzepatide (Mounjaro): Phase 2 readout est. (NCT07825857)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 2.\nStudy: Randomized Controlled
  Trial of Tirzepatide for Methamphetamine Use Disorder\nEstimated primary 
 completion: 1 July 2031. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tirzepatide-mounjaro#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07825857
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07559500-115@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Tirzepatide (Mounjaro): Phase 1 readout est. (NCT07559500)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 1.\nStudy: Tirzepatide s Dopamin
 ergic Effects in Alcohol Use Disorders (AUD)\nEstimated primary completion
 : 31 December 2031. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 irzepatide-mounjaro#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07559500
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
